Connection
Susan Lana to Treatment Outcome
This is a "connection" page, showing publications Susan Lana has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.193 |
|
|
|
-
Wolf-Ringwall A, Lopez L, Elmslie R, Fowler B, Lori J, Sfiligoi G, Skope A, Arnold E, Hughes KL, Thamm DH, Ehrhart EJ, Avery AC, Lana SE. Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. Vet Comp Oncol. 2020 Sep; 18(3):342-352.
Score: 0.052
-
Selmic LE, Lafferty MH, Kamstock DA, Garner A, Ehrhart NP, Worley DR, Withrow SJ, Lana SE. Outcome and prognostic factors for osteosarcoma of the maxilla, mandible, or calvarium in dogs: 183 cases (1986-2012). J Am Vet Med Assoc. 2014 Oct 15; 245(8):930-8.
Score: 0.037
-
Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014 Mar-Apr; 28(2):554-63.
Score: 0.035
-
Mullins MN, Dernell WS, Withrow SJ, Ehrhart EJ, Thamm DH, Lana SE. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc. 2006 Jan 01; 228(1):91-5.
Score: 0.020
-
Nolan MW, Uzan OC, Green NA, Lana SE, Lascelles BDX. Intensity of perioperative analgesia but not pre-treatment pain is predictive of survival in dogs undergoing amputation plus chemotherapy for extremity osteosarcoma. Vet Comp Oncol. 2022 Sep; 20(3):568-576.
Score: 0.015
-
LeBlanc AK, Mazcko CN, Cherukuri A, Berger EP, Kisseberth WC, Brown ME, Lana SE, Weishaar K, Flesner BK, Bryan JN, Vail DM, Burton JH, Willcox JL, Mutsaers AJ, Woods JP, Northrup NC, Saba C, Curran KM, Leeper H, Wilson-Robles H, Wustefeld-Janssens BG, Lindley S, Smith AN, Dervisis N, Klahn S, Higginbotham ML, Wouda RM, Krick E, Mahoney JA, London CA, Barber LG, Balkman CE, McCleary-Wheeler AL, Suter SE, Martin O, Borgatti A, Burgess K, Childress MO, Fidel JL, Allstadt SD, Gustafson DL, Selmic LE, Khanna C, Fan TM. Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. Clin Cancer Res. 2021 06 01; 27(11):3005-3016.
Score: 0.014
-
Curran KM, Schaffer PA, Frank CB, Lana SE, Hamil LE, Burton JH, Labadie J, Ehrhart EJ, Avery PR. BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. Vet Comp Oncol. 2017 Dec; 15(4):1269-1279.
Score: 0.010
-
Petty JC, Lana SE, Thamm DH, Charles JB, Bachand AM, Bush JM, Ehrhart EJ. Glucose transporter 1 expression in canine osteosarcoma. Vet Comp Oncol. 2008 Jun; 6(2):133-40.
Score: 0.006
-
Williams LE, Gliatto JM, Dodge RK, Johnson JL, Gamblin RM, Thamm DH, Lana SE, Szymkowski M, Moore AS. Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995). J Am Vet Med Assoc. 2003 Sep 15; 223(6):825-31.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|